Is Molecular Imaging REQUIRED to Translate the Promise of Molecular Medicine into a Clinical Reality
Matthew O’Donnell教授，美国工程院院士。现任美国University of Washington工程学院教授，Frank & Julie Jungers工程学院院长。电气电子工程师学会（IEEE）Fellow，美国医学与生物工程学会（AIMBE）Fellow。Matthew O’Donnell教授是超声成像专家，利用同步能量源进行非侵入式生物医学成像。他的研究领域主要包括超快光学成像、在体显微技术、冠状动脉导管成像、光声阵列、弹性和分子成像。发表300多篇期刊文章并拥有55项专利，Ultrasound Imaging期刊副主编。
Worldwide,the vast majority of healthcare spending goes to treatment, with only a small fraction of total expenditures devoted to prediction, diagnosis, and treatment monitoring. Traditional methods of disease management are reactive – we wait until someone is sick before treating the disease with expensive procedures. A radical departure from this approach is required to reduce overall costs and improve outcomes. The key is to shift from diagnosing symptomatic patients to detecting disease in a presymptomatic population, i.e. to shift to personalized healthcare delivery. Personalized healthcare enabled by molecular medicine will be predictive and preventative, probing an individual’s unique biology to assess the probability of developing various diseases and then designing appropriate treatments, even before the onset of symptoms. This transformation of healthcare delivery can radically shift healthcare expenditures, reducing the amount spent on treatment and substantially increasing the amount spent on prediction and diagnosis with the expectation that the overall costs of healthcare delivery can be significantly reduced while simultaneously improving outcomes. The fundamental hypotheses driving the molecular imaging studies presented in this talk are that personalized medicine will significantly improve healthcare delivery, molecular imaging and therapy are critical to this paradigm, and ultrasound will be one of the major enablers of molecular imaging and therapy.